Somaxon Pharmaceuticals, Inc. (SOMX) Q2 2012 Earnings Call August 7, 2012 4:30 pm ET Executives Matt Sheldon - IR Richard Pascoe - President and CEO Tran Nguyen - SVP and CFO Analysts Graig Suvannavejh - Jefferies PresentationOperator
Welcome to the Somaxon Pharmaceuticals' second quarter 2012 conference call. (Operator Instructions) I would now like to turn the conference over to our host, Mr. Matt Sheldon, Investor Relations for Somaxon's. Matt Sheldon Good afternoon, everyone, and thank you for joining us today to discuss Somaxon Pharmaceuticals' second quarter 2012 financial results. On the call today are Richard Pascoe, the company's President and Chief Executive Officer; and Tran Nguyen, the company's Senior Vice President and Chief Financial Officer. First some housekeeping issues before we start, earlier today Somaxon issued a news release announcing the company's financial results for the second quarter of 2012. If you have not received this news release, if you'd like to be added to Somaxon's fax and e-mail list to receive company information, or if you would like to change your contact information, please contact Somaxon Investor Relations at 858-876-6500. We encourage everyone to read today's news release as well as Somaxon's quarterly report on Form 10-Q that will be filed later today. In addition, be advised that this conference call is being broadcast live on the Internet at investors.somaxon.com/eventdetail.cfm. A playback of this call will be available and may be accessed at that site. Please note that certain of the information discussed on the call today is covered under the Safe Harbor Provisions of the Private Securities Litigation Reform Act. I caution listeners that during this call Somaxon management will be making forward-looking statements. Actual results could differ materially from those stated or implied by the forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Somaxon's press releases and SEC filings including its annual report on Form 10-K and quarterly reports on Form 10-Q.